On November 5, 2021, the Center for the State Control of Medicines, Equipment and Medical Devices (Cecmed) evaluated the report presented by the Center for Genetic Engineering and Biotechnology (CIGB) that evidences the need for the administration of a booster dose, starting 6 months after completing the approved immunization schedule against COVID-19 in Cuba, consisting of 3 doses of 50 micrograms with an interval of 14 days between each one of these doses.
Available data on the safety and ability of the vaccine to reactivate the immune response were presented.
Abdala is 92% effective against severe symptoms of the disease and 90.7% effective against death from COVID-19.
The strategy for applying the booster dose is gradual and will be defined by the Ministry of Public Health.
comments on